SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-011323
Filing Date
2024-03-26
Accepted
2024-03-26 16:45:18
Documents
15
Period of Report
2024-03-26
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51198
2 ex99-1.htm EX-99.1 14855
  Complete submission text file 0001493152-24-011323.txt   296536

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bfri-20240326.xsd EX-101.SCH 3976
4 XBRL DEFINITION FILE bfri-20240326_def.xml EX-101.DEF 26990
5 XBRL LABEL FILE bfri-20240326_lab.xml EX-101.LAB 37236
6 XBRL PRESENTATION FILE bfri-20240326_pre.xml EX-101.PRE 25610
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6560
Mailing Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801
Business Address 120 PRESIDENTIAL WAY, SUITE 330 WOBURN MA 01801 781-245-1325
Biofrontera Inc. (Filer) CIK: 0001858685 (see all company filings)

IRS No.: 473765675 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40943 | Film No.: 24784294
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)